MW 349.31 Da, Purity >99%. Potent and broad-spectrum anti-fungal agent. Inhibits CYP450-dependent 14-α sterol demethylase, to interfere with ergosterol biosynthesis and inhibit fungal growth. Active in vivo.
Images
Key facts
- CAS number
- 188416-29-7
- Purity
- > 99%
- Form
- Solid
- Molecular weight
- 349.31 Da
- Molecular formula
- C16H14F3N5O
- PubChem identifier
- 71616
- Nature
- Synthetic
Target data
Alternative names
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, 1,4 cineole 2 exo monooxygenase, 1,8-cineole 2-exo-monooxygenase, 11B1, Albendazole monooxygenase, Albendazole sulfoxidase, BK channel, BK channel beta subunit, BK channel subunit beta-1, BKCA alpha, BKCA alpha subunit, BKTM, BKbeta, BKbeta1, CP2B6_HUMAN, CP2C9_HUMAN, CP33, CP34, CP3A4_HUMAN, CPB 6, CPC12, CPC8, CPC9, CPCJ, CYP 2B6, CYP IIB6, CYP2B, CYP2B7, CYP2B7P, CYP2C, CYP2C10, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIC9, CYPIIIA3, CYPIIIA4, Calcium activated potassium channel subfamily M subunit beta 1, Calcium-activated potassium channel, Calcium-activated potassium channel subunit alpha-1, Calcium-activated potassium channel subunit beta, Calcium-activated potassium channel subunit beta-1, Charybdotoxin receptor subunit beta-1, Cytochrome P-450MP, Cytochrome P450 2B6, Cytochrome P450 2C9, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 IIB1, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 NF-25, Cytochrome P450 PB-1, Cytochrome P450 family 2 subfamily B, Cytochrome P450 family 2 subfamily B polypeptide 6, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 phenobarbital inducible, Cytochrome P450 subfamily IIB (phenobarbital inducible), Cytochrome P450 subfamily IIB (phenobarbital inducible) polypeptide 6, Cytochrome P450 subfamily IIB polypeptide 6, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450-PCN1, Drosophila slowpoke like, EFVM, Glucocorticoid inducible P450, HLP, Hbeta1, IIB1, K(VCA)alpha, K(VCA)beta, K(VCA)beta-1, KCMA1_HUMAN, KCMB1_HUMAN, KCNMA, KCNMA1, KCNMB 1, KCa1.1, Large conductance Ca2+ activated K+ channel beta 1 subunit, MGC126680, MGC149605, MGC88320, Maxi K channel, Maxi K channel beta subunit, Maxi K channel subunit beta-1, Maxi Potassium channel alpha, MaxiK, Microsomal monooxygenase, NF 25, Nifedipine oxidase, OTTHUMP00000020135, P450, P450 IIB1, P450 III steroid inducible, P450 MP, P450 PB 1, P450 PCN1, P450, family III, P450C2C, P450C3, P450IIC19, P450IIC9, Potassium large conductance calcium activated channel subfamily M beta member 1, Quinine 3-monooxygenase, S-mephenytoin 4-hydroxylase, SAKCA, SLO, Slo homolog, Slo-alpha, Slo-beta, Slo-beta-1, Slo1, Slowpoke homolog, Taurochenodeoxycholate 6-alpha-hydroxylase, Xenobiotic monooxygenase, cytochrome P-450 S-mephenytoin 4-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, flavoprotein-linked monooxygenase, hSlo, hslo beta, subfamily M subunit alpha-1, subfamily M subunit beta-1
Recommended products
MW 349.31 Da, Purity >99%. Potent and broad-spectrum anti-fungal agent. Inhibits CYP450-dependent 14-α sterol demethylase, to interfere with ergosterol biosynthesis and inhibit fungal growth. Active in vivo.
Key facts
- CAS number
- 188416-29-7
- Purity
- > 99%
- Form
- Solid
- Molecular weight
- 349.31 Da
- Molecular formula
- C16H14F3N5O
- PubChem identifier
- 71616
- Nature
- Synthetic
- Solubility
Soluble in DMSO to 100 mM.
Soluble in ethanol to 100 mM.
- Biochemical name
- Voriconazole
- Biological description
Potent and broad-spectrum anti-fungal agent. Inhibits CYP450-dependent 14-α sterol demethylase, to interfere with ergosterol biosynthesis and inhibit fungal growth. Active in vivo.
- Canonical SMILES
- CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
- Isomeric SMILES
- C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
- InChI
- InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
- InChIKey
- BCEHBSKCWLPMDN-MGPLVRAMSA-N
- IUPAC name
- (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- +4°C
- Appropriate long-term storage conditions
- +4°C
- Storage information
- The product can be stored for up to 12 months
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Cytochrome P450 3A4 also known as CYP3A4 is an enzyme critical to the metabolism of drugs in the human body. It belongs to the cytochrome P450 superfamily and has a molecular mass of about 57 kDa. This enzyme is widely expressed in the liver and small intestine where it performs its metabolic functions. Another related group includes Maxi Potassium channel alpha (SLO) and Maxi Potassium channel beta (KCNMB1) which are important for potassium ion transport across cell membranes. CYP2C9 a parallel enzyme to CYP3A4 plus the extended group of enzymes such as CYP2C8 CYP2C19 and CYP2B6 also play similar roles in metabolism and are found in similar tissue distributions.
- Biological function summary
Proteins like CYP3A4 facilitate the oxidation of organic substances including many pharmaceuticals. It is part of a large complex of enzymes that contribute to the modification and breakdown of molecules. CYP3A4 shares functional roles with homologous proteins like CYP2C9 which also participates in drug metabolism. Maxi Potassium channel proteins including SLO and KCNMB1 contribute to establishing the cell's electrical status and regulating physiological processes such as muscle contraction and neurotransmitter release.
- Pathways
CYP3A4 plays a role in the metabolism pathway particularly the oxidative breakdown of drugs and toxins. It interacts with CYP2C9 in the metabolism of several important drugs forming a critical component of the detoxification process. Similarly Maxi Potassium channels contribute to the cellular signalling pathway by modulating membrane potential alongside related ion channel proteins which supports proper cardiac skeletal and smooth muscle function.
- Associated diseases and disorders
Enzymes such as CYP3A4 along with related proteins like CYP2C9 have links to conditions of altered drug metabolism such as adverse drug reactions due to polymorphic variations in these enzymes. The Maxi Potassium channel proteins can be associated with disorders like cardiac arrhythmias due to their role in ion transport regulation. These relationships highlight the importance of these proteins in maintaining proper metabolic and physiological functions and the consequences when these processes are disrupted.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Chemical Structure - Voriconazole (UK-109, 496), anti-fungal agent (ab141067)
2D chemical structure image of ab141067, Voriconazole (UK-109, 496), anti-fungal agent
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com